The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130.
Shadia Ibrahim Jalal
No relevant relationships to disclose
Nasser H. Hanna
No relevant relationships to disclose
Robin Zon
No relevant relationships to disclose
Gregory A. Masters
No relevant relationships to disclose
Hossein Borghaei
Consultant or Advisory Role - Bristol-Myers Squibb (U); Genentech (U)
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Arisaph Pharmaceuticals; Pfizer
Karuna Koneru
No relevant relationships to disclose
Sunil S. Badve
No relevant relationships to disclose
Nagendra K Prasad
No relevant relationships to disclose
Neeta Somaiah
No relevant relationships to disclose
Jingwei Wu
No relevant relationships to disclose
Zhangsheng Yu
No relevant relationships to disclose
Lawrence H. Einhorn
Consultant or Advisory Role - Celgene (U)